ArticleScience translational medicine2011
Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells.
Article in Science translational medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00512889 (A Pilot Study of the Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma), which is not on this map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of the Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma
Who cites it
65 citing papers in PubMed.
- Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Trial
- Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Trial
- Engineered artificial antigen-presenting cells for tumor immunotherapy: Design strategies, clinical applications, and translational challenges.Materials today. Bio · 2026Review
- CD28-driven ex vivo generation of stem-like memory CD8Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome.Nature reviews. Drug discovery · 2023Review
- Nanodrugs Targeting T Cells in Tumor Therapy.Frontiers in immunology · 2022Review
- The therapeutic potential of multiclonal tumoricidal T cells derived from tumor infiltrating lymphocyte-1derived iPS cells.Communications biology · 2021Article
- Review
- Memory T cells: strategies for optimizing tumor immunotherapy.Protein & cell · 2020Review
- Selective inhibition of low-affinity memory CD8The Journal of experimental medicine · 2019Article
- DNA-Barcoded pMHC Tetramers for Detection of Single Antigen-Specific T Cells by Digital PCR.Analytical chemistry · 2019Article
- Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer.Frontiers in immunology · 2019Article
- Adoptive cell transfer: new perspective treatment in veterinary oncology.Acta veterinaria Scandinavica · 2018Review
- Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma.Melanoma research · 2018Review
- NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma.Cancer immunology, immunotherapy : CII · 2018Article
- A Subset of Human Autoreactive CD1c-Restricted T Cells Preferentially Expresses TRBV4-1Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- [Construction of specific artificial antigen-presenting cells for in vitro activation of CD19 chimeric antigen receptor T cells].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2017Article
- Immunotherapy biomarkers 2016: overcoming the barriers.Journal for immunotherapy of cancer · 2017Article
- Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel.Frontiers in immunology · 2017Review
- Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.Journal for immunotherapy of cancer · 2017Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Although advanced-stage melanoma patients have a median survival of less than a year, adoptive T cell therapy can induce durable clinical responses in some patients. Successful adoptive T cell therapy to treat cancer requires engraftment of antitumor T lymphocytes that not only retain specificity and function in vivo but also display an intrinsic capacity to survive. To date, adoptively transferred antitumor CD8(+) T lymphocytes (CTLs) have had limited life spans unless the host has been manipulated. To generate CTLs that have an intrinsic capacity to persist in vivo, we developed a human artificial antigen-presenting cell system that can educate antitumor CTLs to acquire both a central memory and an effector memory phenotype as well as the capacity to survive in culture for prolonged periods of time. We examined whether antitumor CTLs generated using this system could function and persist in patients. We showed that MART1-specific CTLs, educated and expanded using our artificial antigen-presenting cell system, could survive for prolonged periods in advanced-stage melanoma patients without previous conditioning or cytokine treatment. Moreover, these CTLs trafficked to the tumor, mediated biological and clinical responses, and established antitumor immunologic memory. Therefore, this approach may broaden the availability of adoptive cell therapy to patients both alone and in combination with other therapeutic modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.